2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
The first objective is to investigate whether biofeedback on HRV and voice volume will lead to a larger decrease of IPV compared to treatment as usual (CBT only). Second, to test the premise that IPV perpetrators have trouble self-observing bodily…